MYGN

SEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000012 · edgardoc.xml · derivative · entry 9

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,252

Underlying: Common Stock · 3,973 shares

Expires 2021-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000012 · edgardoc.xml · derivative · entry 8

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,692

Underlying: Common Stock · 948 shares

Expires 2021-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000012 · edgardoc.xml · derivative · entry 7

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,884

Underlying: Common Stock · 1,891 shares

Expires 2021-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 6

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.48 to $32.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 5

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 4

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.99 to $32.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,441

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.30 to $32.72, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,523

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000010 · edgardoc.xml · derivative · entry 7

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,640

Underlying: Common Stock · 28,640 shares

Expires 2021-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000010 · edgardoc.xml · derivative · entry 6

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,280

Underlying: Common Stock · 21,360 shares

Expires 2021-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 5

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,550

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.30 to $31.99, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 4

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,922

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,922

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001238403-21-000008 · edgardoc.xml · nonDerivative · entry 1

SPIEGELMAN DANIEL K · CIK 0001238403 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,129

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $30.65, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-022170 · doc4.xml · nonDerivative · entry 1

Skovronsky Daniel · CIK 0001741474 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,889

F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant.

SEC source: 0000899243-21-022153 · doc4.xml · nonDerivative · entry 1

Reitan Colleen F · CIK 0001740730 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,424

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

SEC source: 0000899243-21-022151 · doc4.xml · nonDerivative · entry 1

Phanstiel S. Louise · CIK 0001471518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,527

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

F2 · balance_after: The Reporting Person previously reported total beneficial ownership of 82,679 shares of common stock held directly and 5,000 shares of common stock held indirectly through The Phanstiel Trust. Except for the acquisition of 12,848 shares of common stock reported in this Form 4, the Reporting Person's total beneficial ownership of shares of common stock has not changed, but this Form 4 corrects the number of shares of common stock held directly by the Reporting Person and held indirectly by the Reporting Person through The Phanstiel Trust.

SEC source: 0001824720-21-000002 · edgardoc.xml · nonDerivative · entry 1

Kumar Rashmi · CIK 0001824720 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,771

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

SEC source: 0001238403-21-000006 · edgardoc.xml · nonDerivative · entry 1

SPIEGELMAN DANIEL K · CIK 0001238403 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,268

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

SEC source: 0001788981-21-000002 · edgardoc.xml · nonDerivative · entry 1

Newcomer Lee Nisley · CIK 0001788981 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,424

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

SEC source: 0001274225-21-000002 · edgardoc.xml · nonDerivative · entry 1

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,527

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

SEC source: 0001379372-21-000002 · edgardoc.xml · nonDerivative · entry 1

DREISMANN HEINRICH · CIK 0001471714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,527

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant.

SEC source: 0001238403-21-000004 · edgardoc.xml · nonDerivative · entry 1

SPIEGELMAN DANIEL K · CIK 0001238403 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,420

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $29.30, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001519749-21-000006 · edgardoc.xml · nonDerivative · entry 1

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,210

F1 · kind: These shares were acquired under the Myriad Genetics, Inc. 2012 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001843872-21-000011 · edgardoc.xml · nonDerivative · entry 1

Haas Kevin Richard · CIK 0001843872 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,113

F1 · kind: These shares were acquired under the Myriad Genetics, Inc. 2012 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001238403-21-000002 · edgardoc.xml · nonDerivative · entry 1

SPIEGELMAN DANIEL K · CIK 0001238403 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,562

F1 · kind: On May 27, 2021, the Company rescinded Mr. Spiegelman's grant of 15,889 restricted stock units granted on December 4, 2020 and reported on the Form 4 filed with the Securities and Exchange Commission on December 7, 2020.

SEC source: 0001219036-21-000008 · edgardoc.xml · derivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,640

Underlying: Common Stock · 19,360 shares

Expires 2021-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000008 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,922

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.97 to $31.98, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001219036-21-000008 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000006 · edgardoc.xml · derivative · entry 3

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,000

Underlying: Common Stock · 40,000 shares

Expires 2021-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001219036-21-000006 · edgardoc.xml · nonDerivative · entry 2

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,922

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001219036-21-000006 · edgardoc.xml · nonDerivative · entry 1

LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001770252-21-000004 · edgardoc.xml · nonDerivative · entry 2

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,119

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001770252-21-000004 · edgardoc.xml · nonDerivative · entry 1

Lambert Nicole · CIK 0001770252 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,009

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853654-21-000004 · edgardoc.xml · nonDerivative · entry 1

Santa Eric · CIK 0001853654 · Chief Growth Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,420

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001519749-21-000004 · edgardoc.xml · derivative · entry 9

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,966 shares

Expires 2021-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001519749-21-000004 · edgardoc.xml · derivative · entry 8

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,000 shares

Expires 2021-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001519749-21-000004 · edgardoc.xml · derivative · entry 7

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,034 shares

Expires 2021-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

SEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 6

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,128

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 5

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · shares: Represents shares of common stock received upon exercise of a stock option award.

SEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 4

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,128

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 3

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · shares: Represents shares of common stock received upon exercise of a stock option award.

SEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 2

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,128

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 1

Hart Jayne B. · CIK 0001519749 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · shares: Represents shares of common stock received upon exercise of a stock option award.

SEC source: 0000899243-21-013711 · doc4.xml · nonDerivative · entry 1

DIAZ PAUL J · CIK 0001194247 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,869

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.